

Pharmacy Regional Newsletter

June 2024

Is the patient the correct one?

There has been a number of recent incidents reported where medicines have been handed out to the wrong person. In order to prevent these incidents occurring, community pharmacy staff should be made aware of the "Are you the right person?" check list. This should be followed when handing out medicines. Before handing over the medication the pharmacy staff should ask the patient or representative to state their name and address, this will confirm that the correct person receives the correct medicines. In some cases, where there is uncertainty the patient should be asked for their date of birth.

What if I know the person very well?

Somewhat counterintuitively, this can actually contribute to errors. We have had a number of incidents where the person collecting is very well known to the pharmacy staff, but staff have inadvertently lifted the wrong bag. A friendly chat distracts and makes it an unnatural conversation to check the collector's name. Some of these involved monitored dosage system (MDS) and resulted in harm to the recipient. So always check the bag label corresponds to the patient as you make that hand over, as well as building in the checks on identity as above.

Labelling error on gabapentin oral solution

Learning from a dispensing incident

Summary: Gabapentin 50mg/ml oral solution labelled in error with five times the prescribed dose.

What happened:


- A repeat prescription for gabapentin **50mg/ml** oral solution:"400mg (8ml) QID" was received by a community pharmacy for a nursing home patient. The prescription did not scan in the pharmacy and so was manually labelled by a member of the pharmacy team with the directions "**40mls four times a day**"
- This incorrect instruction (five times the intended dose) was added to the correct product
- The labelling error was not picked up as part of the pharmacist's clinical or final accuracy check
- The patient's family delivered the dispensed medication to the nursing home where the error was noticed by a nurse when checking the medication into the home

Contributory factors in this incident:

- Distraction or lack of concentration may have contributed to the labelling error
- The labelling error was not picked up through the pharmacist's clinical or final accuracy check

Learning from this incident:

- All staff are urged to take extra care when dispensing liquids for high risk medicines, e.g. gabapentinoids (Schedule 3 controlled drugs):
 - ♦ Robust dispensing SOPs must be in place and followed, and all staff appropriately trained
 - Staff involved in dispensing and labelling should be trained on dose calculations, including converting milligrams (mg) to the equivalent number of millilitres (ml)
 - Prescription directions that require a calculation and/or interpretation should be flagged, for the benefit of the pharmacist when undertaking their final check
 - ♦ The pharmacist, when undertaking their final check, should be vigilant to prescriptions that have required a calculation/interpretation
 - ◊ Consider how the dispensary and workflow can be arranged to minimise noise and distractions.





In this issue

- Is the patient the correct one?
- Labelling error on
 gabapentin oral solution
- Identifying salbutamol overprescribing Maximise asthma control & minimise risk
- Medication errors involving calcium and colecalciferol containing products
- New patient safety standards
- New product Ceyesto[®] (Melatonin 1mg/ml oral solution sugar free)



Identifying salbutamol overprescribing Maximise asthma control & minimise risk

Rates of hospital admissions and mortality for adult asthma in the UK are amongst the worst in Europe¹. Overuse of short acting beta agonists (SABAs) and underuse of inhaled corticosteroids (ICS) are known to be contributing factors to poor asthma control. The *National Review of Asthma Deaths: Why asthma still kills (NRAD²)*, published by the Royal College of Physicians in 2014, found that two thirds of asthma deaths were preventable. Unfortunately, a decade on we're seeing a rise in asthma deaths, not a reduction. In the last 3 years the number of asthma deaths in Northern Ireland has risen by 21%³.



Identifying overuse of SABA inhalers

If an asthma patient is using their reliever inhaler three times a week or more, it's a sign of untreated inflammation in their airways. In theory, any patient using more than six puffs per week of a salbutamol inhaler is over-reliant – that is equal to about 300 puffs per year. As there are 200 puffs per inhaler, **only two inhalers per year should be needed if asthma is well controlled**. Research has shown that 26% of patients in Northern Ireland are prescribed 6 or more SABA inhalers per year.

The 5 things community pharmacists can do that will make a difference

- **Be aware of patients who may be overordering or overusing salbutamol** or other SABA inhalers:
 - When completing the clinical check, consider potential overuse by reviewing PMR records for previous SABA dispensing
 - Check with the patient if they are having to use their SABA more than 3 times per week or if they are experiencing symptoms of poor control
 - ◊ Check previous dispensing patterns if issuing an emergency supply of a SABA
- Discuss asthma control and management
 - \diamond Look for signs of poorly controlled or worsening asthma
- **Check that the patient is using their preventer inhaler.** Underuse of ICS will contribute to poor asthma control. Make sure the patient is taking their preventative inhaler regularly as prescribed
- Ask the patient to demonstrate their inhaler technique and support them if there are areas that can be improved
- **Signpost to useful resources.** There are great resources including self-help courses and <u>inhaler technique videos</u> available for patients from <u>Asthma + Lung UK</u>, <u>Chest Heart & Stroke</u>.



References:

- 1. Global asthma report 2022, The Global Asthma Network (GAN). <u>http://www.globalasthmareport.org/</u> (accessed 11 January 2024)
- 2. Royal College of Physicians. Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry report. London: RCP, 2014
- 3. 'Asthma care is in crisis'. Asthma + Lung UK Released on 24th April 2024

Medication errors involving calcium and colecalciferol containing products

Calcium and colecalciferol containing products come in a wide range of brands and formulations. Within brands, there can be a range of products such as oral tablets, chewable tablets, once daily chewable tablets and effervescent tablets or granules, which vary in composition and licensed dose.

Dispensing incidents involving calcium and colecalciferol containing products have been reported to SPPG. The table below summarises some recent incidents and learning outcomes. Thankfully no harm came to the patients involved.



Image by <u>Racool_studio</u> on Freepik

Intended product / dose	Product dispensed	Contributory Factors	Learning
Accrete D3 [®] One a Day	Accrete D3 [®] Film coated	Same brand name	Calcium salts should be
chewable tablets	tablets	'Accrete D3 [®] ' leading	prescribed by brand name to avoid
		to selection error.	confusion / aid product
Each tablet contains:	Each tablet contains:		identification (as per <u>HSC Items</u>
1000mg of calcium and	600mg of calcium and 400	Mid-cycle monitored	Unsuitable for Generic Prescribing
880 units of colecalciferol.	units of colecalciferol	dosage system	list).
		(MDS) changes.	,
Licensed dose: 1 tablet	Licensed dose: 1 tablet		Check both the brand AND
daily	twice daily		formulation details during the
-	-		checking process.
Accrete D3 One a Day 1000 mg/880 IU Ocewable Tablets	Accrete D3		
A SAMOT	Film-Coated Tablets		Ensure the dose is appropriate for
	Calcium/Colecalciferol Helps to maintain healthy levels of Calcium and Vitamin D		the product being dispensed as
			this could highlight a 'prescribing'
	internis.		error or a 'selection' error.
Calcium carbonate	Calcichew [®] 500mg	The prescription was	Query any discrepancies with the
1.25g / colecalciferol 400	chewable tablets	written generically.	prescriber.
units		whiten generically.	
(e.g. Calcichew D3 Forte [®])		A label was produced	Report software issues and
(e.g. Galcienew Do Forte)		for the correct generic	perform regular software updates.
Each tablet contains:	Each tablet contains:	product but when	This particular issue was resolved
500mg of calcium and 400	500mg of calcium	printed off on the	on the McLernons system in May
units of colecalciferol.		McLernons system it	2024.
units of colecalcherol.		stated Calcichew [®] in	
		brackets, not	A limited variety of products may
		Calcichew D3 forte [®] .	reduce the risk of selection errors.
		Calcicliew D5 lone .	Choose from products on the
Adcal-D3 caplets	Adcal-D3 caplets	Prescribed dose	<u>NI Formulary</u> .
-		differed from licensed	
Each caplet contains:		dose.	
300mg of calcium and 200			
units of colecalciferol.		Non-adherence to	
		SOP.	
Prescribed dose:	Labelled dose:		
1 caplet twice a day	2 caplets twice a day		
	•		·

New product Ceyesto[®] (Melatonin 1mg/ml oral solution sugar free)

NEW Melatonin 1mg/ml oral solution sugar free (licensed product)	Ceyesto [®] 1mg/ml oral solution (sugar free) Summary of Product Characteristics		
	Ceyesto [®] oral solution in the context of paediatrics contains:		
	 Propylene glycol: 52 mg per 1 ml dose. Benzyl alcohol: 6 mg per 1 ml dose. Each 1 ml of oral solution contains 1 mg of sodium. 		
Excipient(s) with known effect	Both ethanol and propylene glycol are substrates of alcohol dehydrogenase, and so there is the potential for accumulation when both are ingested concurrently or repeatedly, especially in young children with low or immature metabolic capacity.		
(EMA ¹ , <u>NPPG and RCPCH</u>) ^{,2} :	The NPPG Position statement 'Choosing an Oral Liquid Medicine for Children' advises on maximum content of propylene glycol and benzyl alcohol dependent on age and weight. Refer to <u>NPPG and RCPCH</u> ² for details.		
	The EMA advises not using products containing benzyl alcohol for more than a week in patients under 3 years of age, unless advised by the doctor or pharmacist ($\underline{EMA \ 2017}^1$).		
Shelf-life	Ceyesto [®] oral solution: once opened must use within 1 month.		
Consideration ³	 When a prescription is presented in the pharmacy for melatonin 1mg/ml oral solution sugar free, the following needs to be considered prior to dispensing Ceyesto[®] against this prescription: Ceyesto[®] is an option for children > 6 years. Excipient content of Ceyesto[®] is not a clinical concern for typical 6-year-old and older by weight. 		

References:

1. Committee for Human Medicinal Products (CHMP), EMA. Questions and answers on benzyl alcohol used as an excipient in medicinal products for human use. EMA/CHMP/508188/2013. 9 Oct 2017. Questions and answers on benzyl alcohol used as an excipient in medicinal products for human use (europa.eu)

- 2. NPPG and RCPCH. Choosing an Oral Liquid Medicine for Children. Position statement 2020-01 Position-Statement-Liquid-Choice-V1-November-2020.pdf (nppg.org.uk)
- 3. <u>Regional Drug and Therapeutics Centre Formulary Assessment Tool</u>. Neonatal &Paediatric Pharmacy Group-Ceyesto melatonin Oral Solution. No 15 February 2024

New Patient Safety Standards

The Royal Pharmaceutical Society (RPS), the Association of Pharmacy Technicians UK (APTUK) and the Pharmacy Forum NI, have updated their joint professional standards that support pharmacists, pharmacy technicians and pharmacy teams responding to patient safety incidents. These can be viewed <u>here</u>.



Information on how to report incidents in NI can be found here.

This newsletter has been produced for GP practices and community pharmacies by the Regional Pharmacy and Medicines Management Team. If you have any queries or require further information on the contents, please contact one of the <u>Pharmacy Advisers</u>.

Every effort has been made to ensure that the information included in this newsletter is correct at the time of publication. Throughout the newsletter, external links are provided to other sites. These links are provided to improve access to information and exist only for the convenience of readers of the Newsletter; SPPG cannot accept responsibility for their content. The SPPG does not necessarily endorse the views expressed within these external websites. We cannot guarantee that these links will work all of the time and we have no control over the availability of the linked pages. This newsletter is not to be used for commercial purposes.